Protective effects of Astragaloside Ⅳ on early kidney damage in diabetes mellitus rats and its mechanisms

doi:10.12092/j.issn.1009-2501.2018.03.003

Abstract

Abstract:

AIM: To study the effects of Astragaloside Ⅳ (AS-Ⅳ) on early kidney damage and the mechanisms in diabetes mellitus rats induced by Streptozotocin (STZ). METHODS: The diabetic rats model was established by intraperitoneal injection with STZ (55 mg/kg) and the model rats were randomly divided into model group，AS-Ⅳ (20, 40, 80 mg/kg) group. After 8 weeks of administration, body weight, blood glucose, 24 hours urinary protein excretion rate (24 h UAER), the level of serum creatinine (Scr), urea nitrogen (BUN) , serum SOD, GSH-Px activity and MDA content were measured. HE and PAS staining were used to observe renal histopathology and Western blot was used to detect the expression of TGF-β1, Nrf2 and HO-1.RESULTS:Compared with control group, the blood glucose, kidney index, MDA content and the level of Scr, BUN, 24 h UAER and expression of TGF-β1, total protein of Nrf2 and nucleus protein of Nrf2 increased significantly and the serum SOD and GSH-Px activity decreased significantly in diabetes mellitus model group. Compared with model group, AS-Ⅳ(40, 80 mg/kg) group could decrease MDA content , the level of Scr, BUN, 24 h UAER and increase serum SOD and GSH-Px activities, expression of TGF-β1 was decreased by AS-Ⅳ(80 mg/kg) group, expression of total Nrf2, nucleus Nrf2 and HO-1 were increased by AS-Ⅳ(80 mg/kg) group.CONCLUSION:AS-Ⅳ can inhibit renal oxidative stress injury. The meachanism may be related to increasing the serum antioxidant activity and reducing the expression of TGF-β1, activation of Nrf2 pathway, upregulating the expression of antioxidative protein in HO-1.

Key words: diabetes mellitus, astragaloside Ⅳ, TGF-β1, Nrf2

CLC Number:

R965.2

LI Zhuqing, JU Yinghui, CHEN Qingqing, MA Keke, LI Weiping. Protective effects of Astragaloside Ⅳ on early kidney damage in diabetes mellitus rats and its mechanisms[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2018, 23(3): 255-262.

References

［1］Bhattacharjee N, Barma S, Konwar N, et al. Mechanistic insight of diabetic nephropathy and its pharmacotherapeutic targets: An update［J］.Eur J Pharmacol,2016,791: 8-24.
［2］Fernandes SM, Cordeiro PM, Watanabe M, et al. The role of oxidative stress in streptozotocin-induced diabetic nephropathy in rats［J］.Arch Endocrinol Metab,2016,60(5): 443-449.
［3］冀晓俊，李昂，段美丽，等. 黄芪甲苷对体外炎症状态下单核细胞NF-κB 及糖皮质激素受体表达的影响［J］. 中国临床医学，2010，17（4）：590-593.
［4］许亮，陈春富. 黄芪甲苷对大鼠脑缺血再灌注后星形胶质细胞的影响［J］.山东大学学报（医学版），2011，49（8）：26-30.
［5］曹玲玲，李维祖，司秀莲，等. 黄芪甲苷对肾小球系膜细胞氧化应激损伤的保护作用及其机制［J］. 中国中药杂志，2013，38（5）：725-730.
［6］陈博南，陈刚毅. 黄芪甲苷对糖尿病肾病大鼠肾脏的保护机制初步研究［J］. 云南中医中药杂志，2016，37（2）：58-60.
［7］Miranda-Díaz AG , Pazarín-Villaseor L, Yanowsky-Escatell FG, et al. Oxidative stress in diabetic nephropathy with early chronic kidney disease［J］.J Diabetes Res,2016: 704-723.
［8］陈澍，曾令奋，张一萍. 益肾汤对糖尿病大鼠肾组织磷酸化smad2/3的影响［J］. 时珍国医国药，2012，23（10）：2544-2546.
［9］Giribabu N, Karim K, Kilari EK, et al. Phyllanthus niruri leaves aqueous extract improves kidney functions, ameliorates kidney oxidative stress, inflammation, fibrosis and apoptosis and enhances kidney cell proliferation in adult male rats with diabetes mellitus［J］.J Ethnopharmacol,2017,205: 123-137.
［10］Nasiri A, Ziamajidi N, Abbasalipourkabir R, et al. Beneficial effect of aqueous garlic extract on inflammation and oxidative stress status in the kidneys of type 1 diabetic rats［J］.Ind J Clin Biochem,2017,32(3): 329-336.
［11］刘小娜，王兰英，彭建霞，等. 荞麦黄酮对大鼠糖尿病肾病的保护作用［J］.中国实验方剂学杂志，2015，21（2）：142-145.
［12］Lo CS, Chang SY, Chenier I, et al. Heterogeneous nuclear ribonucleoprotein suppresses angiotensinogen gene expression and attenuates hypertension and kidney injury in diabetic mice［J］.Diabetes,2012,61(10): 2597-2608．
［13］Lee HB, Seo JY, Yu MR. Radical approach to diabetic nephropathy［J］.Kidney Int Suppl,2007,72(106): 67-70.
［14］刘晓云，张文，李卫平，等. 黄芪总苷对糖尿病小鼠肾脏保护作用的研究［J］.中国临床药理学与治疗学，2017，22（2）：132-138.
［15］熊莉，李维组，孙立，等. 黄芪甲苷对高糖诱导人肾小球系膜细胞损伤的保护作用及其机制［J］. 安徽医科大学学报，2014，49（9）：1274-1278.
［16］Loboda A, Damulewicz M, Pyza E, et al. Role of Nrf2/HO-1 system in development, oxidative stress response and diseases: an evolutionarily conserved mechanism［J］.Cell Mol Life Sci,2016,73(17): 3221-3247.
［17］Haan JB. Nrf2 activators as attractive therapeutics for diabetic nephropathy［J］. Diabetes, 2011,60(11): 2683-2684.
［18］李谌，黄维义. 血红素氧合酶1的生物学特性及其在冠心病防治中的作用［J］.中国动脉硬化杂志，2016，24（1）：92-96.
［19］黄小平，邓常清，邱咏园，等. 黄芪甲苷和三七的三种有效成分配伍对小鼠脑缺血/再灌注后氧化应激和Nrf2/HO-1途径的影响［J］. 中国药理学通报，2013，29（11）：1596-1601.
［20］Shang G, Tang X, Gao P, et al. Sulforaphane attenuation of experimental diabetic nephropathy involves GSK-3β/Fyn/Nrf2 signaling pathway［J］.J Nutr Biochem, 2015,26(6): 596-606.
［21］黄存东，徐源，李竹青，等. 黄芪甲苷对高糖环境下人肾小球系膜细胞损伤保护作用及其机制研究［J］. 安徽医科大学学报，2017，52（7）：972-978.

[1]	MA Yan, TIAN Gaopeng, SHI Xingwen, SUN Ting, XIE Jingjing, ZHEN Donghu. Correlation between 25(OH)D and metabolically related fatty liver in T2DM population [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(9): 1018-1026.
[2]	HOU Ruiying, GUO Lige, JIAO Weijie, DU Lei, WU Guiyue, ZHAO Xu. Effects of Xiaokeshu recipe on levels of serum inflammatory factors in type2 diabetic rats and its mechanism [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(4): 377-382.
[3]	HOU Xiaoyu, LENG Yufang, CAO Xuefen, LV Xingjiao, HAN Xiaoxia, Janvier NIBARUTA, LIU Yongqiang. Network analysis and experimental verification of Schisandrin B reduces intestinal ischemia reperfusion injury [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(2): 147-154.
[4]	ZHAI Weiwei, YU Qiaoling, LIU Ping, QIU Bo, WU Huizhen. Research progress of finerenone in the treatment of type 2 diabetes mellitus complicated with chronic kidney disease [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2022, 27(9): 1067-1074.
[5]	LU Senlin, LIU Xinyuan, WANG Jili, HUANG Xiaofei. Research progress of virus-mediated gene therapy in type 2 diabetes mellitu [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2022, 27(7): 800-807.
[6]	ZHANG Li, WANG Jin, LI Huizi, PENG Hui, HE Jun, PENG Shuangqing, GUO Jiabin. Role of Nrf2 pathway in flutamide-induced mitochondrial biogenesis [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2022, 27(5): 498-504.
[7]	DAI Hongyu, YANG Kun, HU Ruchun, ZHOU Hongmei, MA Peimin, HAO Qian. Duration time and effectiveness of 0.25%ropivacaine for sciatic nerve block in patients with diabetes [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2022, 27(11): 1278-1284.
[8]	WANG Wenjuan, QI Mingrui, TIAN Limin. Research progress on Nrf2 in diabetic cardiomyopathy and intervention of traditional Chinese medicine [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2022, 27(10): 1163-1170.
[9]	LIU Xiaoping, LAI Xiangmao, OUYANG Zizhang, JIANG Sheng, ZHANG Ying. Nobiletin inhibits neonatal rat cardiomyocytes hypertrophy induced by high glucose [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2021, 26(7): 753-759.
[10]	WU Yi, FANG Fang, CHEN Ying, Fan Junwei. Influence of donor and recipient CYP3A5 genotype on tacrolimus trough concentrations in the early stage after liver transplantation and its clinical significance [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2021, 26(6): 631-639.
[11]	XU Yongxia, XIE Mingzhu, GONG Muxue, HUANG Jiaying, ZHAO Li, ZHU Defa. Effects of 25(OH)D on islet β-cells function in the elderly with type 2 diabetes [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2020, 25(9): 1021-1026.
[12]	ZHAO Hailing, ZHANG Haojun, ZHAO Tingting, YAN Meihua, DONG Xi, MA Liang, LI Ping. Association between the polymorphism of PNPLA2 gene and the risk of ischemic stroke in type 2 diabetic patients in Chinese Han Population [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2020, 25(6): 664-669.
[13]	HUANG Hao, XIAO Fang, JIA Hong, WANG Xiaoshuang, DUAN Yating. miR-138-5p protects β cell function by regulating HIF-1α in gestational diabetes mellitus [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2020, 25(5): 489-497.
[14]	ZHANG Xiaoling，GUAN Qiaobin，YANG Yi, GUO Li，HAN Chenyang. Effect of interleukin 12A on proliferation and differentiation of CD4+CD25+Foxp3+Treg [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2019, 24(5): 496-502.
[15]	HE Yang, SONG Liying, PENG Xiangdong, FANG Weijin, WANG Chunjiang, DENG Zhenzhen, LIU Shikun. Protective effects of Cordyceps sinensis powder on liver injury induced by DEN in rats and the effect of TGF-β1/Smads pathway [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2018, 23(9): 974-982.